Three GenAI Workflow Platforms Raise $87M as Enterprises Move Past Copilot Pilots

Three workflow-automation vendors raised $87 million in the past week, marking a decisive shift in enterprise GenAI investment from copilot pilots to production workflow platforms.

Skan AI announced $63 million in funding co-led by Cathay Innovation and Dell Technologies Capital, alongside general availability of its workflow-native GenAI platform. Fisent Technologies closed $4.3 million from FINTOP to expand applied GenAI process automation in regulated enterprises. June emerged from stealth with $20 million in pre-seed funding from Marc Benioff's Time Ventures to address AI deployment bottlenecks. The combined capital and investor profiles—Dell Technologies, Citi Ventures, State Farm Ventures, Michael Dell, Aaron Levie, George Kurtz—signal that enterprise buyers are moving budget from proof-of-concept projects to platforms that automate multi-step business processes.

Why this matters for enterprise buyers

These three platforms compete in different segments of the GenAI workflow stack, but they share a common thesis: enterprises need workflow-centric architectures, not text-generation layers bolted onto existing tools. Skan AI models how businesses actually operate by building a "context graph of work," then deploys agents that automate across systems. Fisent targets regulated workflows in financial services with guardrails built for compliance. June scans existing enterprise systems to identify technical and operational bottlenecks that block AI deployment before they happen.

For CIOs evaluating GenAI platforms, this represents a category shift. Traditional process mining vendors like Celonis and UiPath added GenAI features but still rely on event logs rather than observed workflow behavior. Hyperscaler GenAI tools like Microsoft Copilot and Google Gemini for Workflows provide text generation but lack native process intelligence. Skan AI positions itself against both: a GenAI-native platform that models workflows from observation, then ties agents to that model.

Budget and risk implications

Skan AI's investor base matters for enterprise procurement. Dell Technologies Capital and Wipro Ventures participation suggests the platform will be sold through infrastructure and services channels, requiring enterprises to reserve budget for implementation services plus platform licensing rather than SaaS-only models. For operations and back-office leaders, this shifts GenAI spend from "AI innovation" budget lines into process automation and operations excellence budgets, where ROI requirements are stricter and procurement cycles are longer.

Fisent's $4.3 million round from FINTOP is smaller but strategically significant. FINTOP's LP network includes approximately 100 banks and financial services companies, giving Fisent immediate access to referenceable customers and potentially co-funded pilots. For compliance and risk officers in regulated industries, this addresses the primary objection to horizontal GenAI platforms: lack of domain-specific controls and auditability. Fisent's explicit focus on "Applied GenAI Process Automation for Regulated Enterprises" means its roadmap will prioritize regulatory reporting and audit trails, not feature velocity.

June's $20 million pre-seed round is unusually large for a company emerging from stealth. The investor list—Marc Benioff, Michael Dell, Aaron Levie, George Kurtz—suggests the platform addresses a widely acknowledged problem: most GenAI projects fail in deployment, not conception. June competes with consulting-heavy AI transformation programs from the Big 4 and global system integrators, which manually audit systems and processes before GenAI rollouts. The platform automates that discovery process, mapping current business processes and identifying technical bottlenecks. For enterprises with complex legacy estates, this reduces the time and cost required to achieve AI readiness.

What to watch

The velocity of funding into workflow-specific GenAI platforms indicates that enterprise buyers are past the "Will GenAI work?" question and into the "Which architecture do we standardize on?" phase. Enterprises evaluating these platforms should focus on three decision points. First, does the platform model workflows from observation or require manual configuration? Platforms that build workflow context automatically reduce implementation risk. Second, does the vendor roadmap prioritize compliance and auditability, or feature breadth? Regulated industries cannot deploy platforms that treat governance as an afterthought. Third, what is the total cost of deployment, including professional services? Platforms sold through SI channels often carry hidden implementation costs that exceed the software license.

For enterprise buyers shortlisting GenAI workflow platforms in 2026, the relevant competitive set now includes Skan AI, Fisent, and June alongside incumbents like Celonis, UiPath, and the hyperscaler GenAI stacks. The funding velocity and investor quality suggest these vendors will be viable alternatives with enterprise-grade support within six months. Budget conversations should account for higher upfront implementation costs in exchange for lower operational risk and faster time to production.